Stockreport

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases [Seeking Alpha]

Annexon, Inc. - common stock  (ANNX) 
PDF Tanruprubart's Phase III results are promising, but there is U.S. regulatory uncertainty due to non-U.S. trial sites and dose-response questions. Vonaprument's Phase [Read more]